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Colorectal cancers (CRCs) initiate through distinct mutations, including in APC pathway 
components leading to tubular adenomas (TAs); in BRAF, with epigenetic silencing of CDX2, 
leading to serrated adenomas (SAs); and in the DNA mismatch repair machinery driving 
microsatellite instability (MSI). Transformation through the APC pathway involves loss of the 
hormone GUCA2A that silences the tumor suppressing receptor GUCY2C. Indeed, oral hormone 
replacement is an emerging strategy to reactivate GUCY2C and prevent CRC initiation and 
progression. Moreover, retained expression by tumors arising from TAs has established GUCY2C 
as a diagnostic and therapeutic target to prevent and treat metastatic CRC. Here, we defined the 
potential role of the GUCA2A-GUCY2C axis, and its suitability as a target, in tumors arising 
through the SA and MSI pathways. GUCA2A hormone expression was eliminated in TAs, SAs and 
MSI tumors compared to their corresponding NATs. In contrast to the hormone, the tumor 
suppressing receptor GUCY2C was retained in TA and MSI tumors. Surprisingly, GUCY2C 
expression was nearly eliminated in SAs reflecting loss of the transcription factor CDX2. Changes 
in the GUCA2A-GUCY2C axis in human SAs and MSI tumors were precisely recapitulated in 
genetic mouse models. These data reveal the possibility of GUCA2A loss silencing GUCY2C in the 
pathophysiology of, and oral hormone replacement to restore GUCY2C signaling to prevent, MSI 
tumors. Also, they highlight the potential for targeting GUCY2C to prevent and treat metastases 
arising from TA and MSI tumors. In contrast, loss of GUCY2C excludes patients with SAs as 
candidates for GUCY2C-based prevention and therapy. 
KEYWORDS: serrated adenoma, tubular adenoma, colorectal cancer, guanylin, guanylate cyclase 
C, CDX2  
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Colorectal cancer (CRC) is a heterogeneous disease, which can be classified into molecular 
subtypes originating through distinct biological pathways with some degree of overlap (1). The 
conventional neoplasia pathway accounts for ~75% of CRCs and is frequently associated with 
chromosomal instability (CIN)(1). This pathway is often linked to ligand-independent 
upregulation of canonical WNT signaling due to a loss-of-function mutation in the APC 
(Adenomatous Polyposis Coli) gene, facilitating nuclear translocation of β-catenin that promotes 
increased expression of proto-oncogenic targets such as c-MYC and CYCLIN-D1 (2). The 
premalignant adenomatous polyps that arise from this pathway are often noted to have tubular, 
tubulovillous or villous histology (3). On the other hand, ~20% of all CRCs originate from serrated 
precursor lesions that exhibit serrated or saw-tooth dysplastic crypts, and are subdivided into 
traditional serrated adenomas (TSA) or sessile serrated adenomas (SSAs) (4). Adenomatous 
transformation and progression to carcinomas in the serrated pathway reflect molecular 
alterations rarely seen in the conventional pathway. Thus, mutations in the mitogen-activated 
protein kinase (MAPK) components, such as KRAS or BRAF, are early events in the serrated 
pathway (5, 6). Oncogenic BRAF (usually V600E) mutations are identified in only 10% of all CRCs, 
but 70-80% of SSAs, and are associated with a worse prognosis (6). 
Further, serrated lesions are characterized by epigenetic silencing of various genes by 
methylation (CpG island methylator phenotype or CIMP) (5, 7). CIMP can silence tumor 
suppressor genes such as p16, IGF2, MGMT, AXIN2, MCC and CDX2 (5, 7, 8). CDX2 is a caudal-
type homeobox transcription factor that promotes intestinal homeostasis along the constantly 
renewing crypt villus axis, provides tissue identity to stem cells, and has emerged as a tumor 
suppressor (9, 10). The lack of CDX2 expression in CRC is associated with decreased 5-year 
disease-free survival and overall poor prognosis independent of tumor stage, grade, age and 
gender (10). Interestingly, BRAF mutations and loss of CDX2 expression occur together frequently 
in serrated tumors and are associated with worse prognosis (6, 11). 
In addition, a hypermutable phenotype known as microsatellite instability (MSI) pathway 
accounts for 12-17% of all CRCs (8). MSI results from a loss of genomic replicative fidelity due to 
deficiencies of the DNA mismatch repair (MMR) machinery. The hereditary subtype of MMR 
deficiency, also called Lynch syndrome or hereditary non-polyposis CRC (HNPCC), accounts for 
3% of MSI tumors , and is characterized by germline mutations or epimutations in one or more 
of the 4 MMR genes; MSH2, MLH1, MSH6 and PMS2 (8, 12). In contrast, sporadic MSI tumors are 
characterized by biallelic methylation of the MLH1 promoter and functional loss of MLH1 and 
PMS2 proteins (8, 12). Interestingly, sporadic MSI tumors are associated with a background of 
CIMP and harbor the BRAF (V600E) mutation in half of cases, which is associated with a worse 
prognosis (8, 12, 13). Thus, the serrated neoplasia phenotype can be associated with sporadic 
MSI; indeed, they are not mutually exclusive. 
Guanylate cyclase C (GUCY2C) is a transmembrane receptor expressed on apical surfaces of 
enterocytes in small intestine, colon and rectum, where it surveys the lumen for its peptide 
ligands (14). The intestine expresses two peptide hormones that function as paracrine 
endogenous GUCY2C ligands, uroguanylin (GUCA2B) and guanylin (GUCA2A) in the small and 
large intestine, respectively (14). In addition, GUCY2C is the intestinal target for enterotoxigenic 
bacterial heat-stable enterotoxins, which are structurally analogous to its endogenous ligands 
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and the pathogenic basis for traveler’s diarrhea (14, 15). Once activated, GUCY2C produces the 
second messenger cyclic guanosine monophosphate (cGMP), activating downstream effectors 
such as cGMP-dependent protein kinase, which phosphorylates the cystic fibrosis 
transmembrane conductance regulator channel promoting salt and water secretion (15). 
Beyond fluid homeostasis, GUCY2C has emerged as a tumor suppressor, and transformation is 
associated with the loss of guanylin expression which silences receptor signaling and disrupts 
intestinal homeostasis to promote CRC (16, 17). Indeed, GUCA2A expression is lost, while 
GUCY2C is retained, in human colorectal cancers, as well as in adenomas in ApcMin mice and 
patients with familial adenomatous polyposis, reflecting the conventional pathway of 
tumorigenesis (18-20). In that context, GUCA2A loss coupled with retention of GUCY2C provides 
a unique opportunity for primary chemoprevention of the conventional pathway of 
transformation, by reactivating receptor signaling through oral hormone replacement (19). 
Further, retention of GUCY2C by metastatic tumors arising by the conventional pathway of 
transformation from the colorectum also has emerged as a mucosally restricted tumor-
associated antigen that is a diagnostic marker (20) and therapeutic target for cancer vaccines, 
adoptive cell therapies and antibody-drug conjugates (21). In that regard, luminal 
compartmentalization in apical membranes of normal epithelial cells, but systemic exposure in 
metastatic tumors, makes GUCY2C a unique target for systemic therapies, eliminating extra-
intestinal deposits of cancer without adverse effects on the normal intestinal mucosa (22). 
The roles of silencing the GUCA2A-GUCY2C signaling axis in the pathogenesis of, and the potential 
utility of GUCY2C as a chemoprevention and therapeutic target in, tumors that arise from the 
conventional pathway involving mutations in APC or CTNNB1 genes are established. However, 
changes in expression of GUCA2A or GUCY2C, and the associated utility of the receptor in 
chemoprevention and targeted therapeutic paradigms, in tumors that arise by SA and MSI 
pathways remain unknown. Here, we define the expression of GUCY2C and GUCA2A in tubular 
adenomas (TAs), serrated adenomas (SAs), and MSI tumors and their normal adjacent tissues 
(NATs). 
2. MATERIALS AND METHODS 
HUMAN TUMOR TISSUES AND HISTOLOGICAL INTERPRETATION 
The study was approved by the institutional review board of Thomas Jefferson University (IRB 
control #14D.376). To investigate GUCA2A and GUCY2C protein and mRNA expression, we 
obtained human tissues as formalin-fixed paraffin-embedded (FFPE) blocks from 47 patients 
from the archives of Department of Pathology at Thomas Jefferson University Hospital and 
Cooperative Human Tissue Network (CHTN: https://www.chtneast.org). These included normal 
colon (n=7), tubular adenomas (n=18), serrated adenomas (n=15), MSI tumors (n=7) and, where 
available, their matched NATs. The diagnosis of serrated lesions and MSI tumors was made based 
on established histopathologic criteria by a board-certified gastrointestinal pathologist (J.P.) (4, 
8). Tumors and their matched normal epithelia were labeled on the hematoxylin- and eosin 
(H&E)-stained tissue sections by a Pathologist (E.G.) blinded to immunofluorescence (IF) results. 
Clinicopathologic data included patient age, sex, location of tumor (proximal colon was classified 
as proximal to the splenic flexure and the remaining region was defined as distal), and 
clinicopathologic subtypes and is summarized in Table 1. 
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2.1. MOUSE TISSUES 
CDX2P-CreERT2 mice express Cre-ERT2 under the control of CDX2 promoter/enhancer regions, 
enabling tamoxifen-inducible targeting of loxP alleles from the ileal to rectal epithelium. Cdx2fl/fl 
mice exhibit biallelic Cdx2 loss (Cdxfl/fl) following Cre-mediated recombination. BrafCA mice 
express normal BRAF prior to Cre exposure and mutationally-active BRAFV600E following Cre-
mediated recombination (23). Four m-thick tissue sections from tamoxifen-treated and  
-untreated mice harboring these transgenes were used for the work here (24) These included 
eight serrated cecal tumors with compound Cdx2 loss and BrafV600E expression. Selected tissues 
from wild type and CreERT2-negative control mice also were used for comparison (24). Also, 
Msh2fl/fl mice with a constitutively active vil-Cre transgene were acquired (25). Tumors harvested 
from Msh2fl/fl mice, predominantly located in small intestine, were fixed in formalin and 
embedded in paraffin for histology and flash frozen in liquid nitrogen for protein and mRNA 
analysis. All mice were C57BL/6 and animal husbandry was compliant with local IACUC standards. 
2.2. RNA ISOLATION 
Total RNA was isolated from animal tissues using RNeasy RNA extraction kits (Qiagen, 
Germantown, MD). Also, total RNA was extracted from human FFPE blocks. At least 20-micron 
slices of tissue (up to 4x) were cut using a microtome. Tissue slices were de-paraffinized using 2 
applications of Citra Solv detergent (Citra Solv LLC, Danbury, CT) overnight at room temperature 
(RT). After removing Citra Solv, samples were washed with ethyl alcohol x 3. Air-dried samples 
were incubated in at least 90 µL of digestion buffer containing 0.1 M NaCl (AM9760G, Life 
Technologies, Carlsbad, CA), 10 mM Tris (AM9855G, Life technologies), 1 mM EDTA (AM9260G, 
Life Technologies), 0.75% sodium dodecyl sulfate (AM9822, Life technologies) and 10 µL of 
proteinase K solution (AM2548, Life Technologies) at 56°C overnight. Proteinase K was then heat-
inactivated by placing the solution at 90°C for 5 min and samples subjected to extraction with 
RNeasy kits (Qiagen). RNA was eluted from RNeasy column using molecular grade water, 
concentration determined by spectrophotometry, and stored at −80°C. 
2.3. QUANTITATIVE REVERSE TRANSCRIPTION (RT)-PCR (QRT-PCR) 
Relative mRNA levels of GUCY2C, GUCA2A and GUCA2B (relative to GAPDH levels) in both human 
and mouse tissue were determined by quantitative real-time reverse transcription-polymerase 
chain reaction (qRT-PCR) by using commercially available primer-probe sets (for mouse: Gucy2c, 
Mm01267705_m1; Guca2a, Mm00433863_m1; Gapdh, Mm99999915_g1; Guca2b, 
Mm01192051_m1; for human: GUCY2C, Hs00990129_m1; GUCA2A, Hs00157859; GAPDH, 
Hs02758991_g1; [Life technologies]). Target mRNA was amplified from total RNA using RNeasy 
mini kits (Qiagen) in a 25 µL reaction on an ABI 7000 Sequence Detection System (Applied 
Biosystems, Foster City, CA).  
2.4. IMMUNOBLOT ANALYSIS 
Protein was extracted from mouse tissues lysed in M-PER reagent (Pierce, Rockford, IL) 
containing phosphatase and protease inhibitor cocktails (Roche, Indianapolis, IN) and 
Benzonase® nuclease (Sigma, St Louis, MO). Lysates were resolved by SDS-PAGE (NuPAGE 4-12% 
Bis-Tris Gel; Novex Life Technologies) and transferred to a nitrocellulose membrane (Novex Life 
Technologies). Membranes were blocked in 10% milk (non-fat dry milk, M0841, LabScientific, 
Highlands, NJ) in PBST (1XPBS and 1% Tween 20) and probed overnight with antibodies to: 
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GUCY2C [1:500; Ms20 (26)], GAPDH (1:5,000; Cell Signaling Technologies, Danvers, MA), GUCA2A 
(1:1000) and GUCA2B (1:1000) followed by incubation with goat anti-mouse horseradish 
peroxidase (HRP)-conjugated and goat anti-rabbit HRP-conjugated secondary antibodies 
(1:30,000; Jackson ImmunoResearch, West Grove, PA). Rabbit anti-GUCA2A (#2538) and anti-
GUCA2B (#6910) antisera used for detecting mouse tissue guanylin and uroguanylin, respectively, 
were a gift from M. Goy (University of North Carolina) (27). Blots were developed in SuperSignal 
West Dura enhanced chemiluminescence substrate (Thermo Scientific, Waltham, MA). Relative 
intensity was quantified by densitometry using ImageJ software (v1.51s, National Institute of 
Health, Bethesda, MD) and normalized to the intensity of GAPDH. 
2.5. IMMUNOFLUORESCENCE STAINING AND SIGNAL QUANTIFICATION 
Sections (4 µm) were obtained from human and mouse specimens in FFPE blocks. After tissue 
de-paraffinization and rehydration, slides were subjected to heat-induced epitope retrieval by 
boiling in a pressure cooker for 15 min in pH 9 antigen retrieval buffer (Dako, Carpinteria, CA). 
Protein expression was determined by following primary antibodies for immunostaining: mouse 
anti-β-catenin IgG1 (1:100, sc-7963, Santa Cruz Biotechnology, Dallas, TX); rabbit anti-CDX2 
conjugated with Alexa Fluor 647 (1:500, ab195008, Abcam, Cambridge, MA); rabbit anti-GUCA2A 
for human guanylin (1:500, HPA018215, Sigma-Aldrich, Saint Louis, MO), mouse anti-GUCY2C 
IgG2a (2 µg/mL; Ms20 (26)), rabbit anti-GUCA2A (1:1000) and rabbit anti-MSH2 (1:100, D24B5, 
Cell Signaling Technology, Danvers, MA). Slides were stained according to a modified Alexafluor 
protocol (Life Technologies; Carlsbad, CA) or tyramide signal amplification protocol (28). 
Appropriate negative controls were employed to improve specificity of IF staining. Thus, GUCA2A 
blocking peptide (APREST72418, Sigma, St. Louis, MO) was pre-incubated with primary antibody 
at the manufacturer’s recommended concentration. Mouse IgG2a isotype control was used as a 
GUCY2C negative control (Biolegend, San Diego, CA). For all runs of IF, normal tissue served as a 
positive control. All images were captured using EVOS™ FL auto imaging system (Life 
Technologies) with a 20X objective. To quantify GUCA2A, GUCY2C, CDX2 and MSH2 protein 
expression, a single in-focus plane was acquired. Using ImageJ software, quantification in defined 
regions of interest (ROIs) was performed by calculating corrected total cell fluorescence (CTCF), 
using the following equation: [CTCF = integrated density – (area of selected cell X mean 
fluorescence of background readings)]. CTCF for each tissue section was calculated relative to 
control ROI. 
2.6. GENE EXPRESSION DATA 
We obtained log 2-transformed GUCY2C-GUCA2A gene expression data from colonic tissue in 
Cdx2fl/fl, BrafV600E, Wt control mice as well as in serrated tumors from compound Cdx2fl/fl and 
BrafV600E mice from Gene Expression Omnibus (GEO; accession number GSE85650)(24). We 
obtained the cancer genome atlas (TCGA)(29) gene expression data using UCSC genome browser 
(available at: http://xenabrowser.net) to compare GUCA2A-GUCY2C-CDX2 expression in human 
CRCs and normal colonic tissue. We classified human CRCs into MSI and microsatellite stable 
(MSS) tumors to compare GUCA2A and GUCY2C gene expression (Supplementary Figs. 1-2). MSI 
was defined by reduced expression in one or more of following MMR genes: MLH1, MSH2, MSH6 
and PMS2. 
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2.7. STATISTICAL ANALYSIS 
Statistical significance was analyzed using Student’s t test, one-way ANOVA and Pearson’s 
correlation coefficient. All p values were two-tailed with p<0.05 considered statistically 
significant. P-values were corrected for multiple testing using Bonferroni’s method. Sample sizes 
of mouse and human tissues were based on experience with previous similar experiments. All 
statistical analyses were performed using GraphPad Prism version 7 (La Jolla, CA). Analyses 
represent mean ± SEM, unless otherwise indicated, and * p<0.05, ** p<0.01, *** p<0.001, ****, 
p<0.0001. 
3. RESULTS 
3.1. PATIENT CHARACTERISTICS 
Cohorts with SAs and TAs were balanced with respect to age and gender (p>0.05; Table 1). 
Patients in the normal colon and MSI tumor cohorts also were balanced with respect to age and 
gender (p>0.05; Table 1). SAs and MSI tumors were located predominantly in proximal colon, in 
agreement with previous observations, whereas TAs were distributed equally between proximal 
and distal colon. TAs included all major histologic subtypes including tubular, tubulovillous and 
villous adenomas. In addition, adenomas from patients with FAP also were analyzed. SAs included 
both major pathogenic subtypes, SSA and TSA. The MSI tumor cohort included both sporadic and 
hereditary subtypes. 
3.2. TUBULAR ADENOMAS 
In close agreement with earlier transcriptomic analyses (18, 19), GUCA2A protein and mRNA 
expression was eliminated in TAs (Fig. 1A-E). As demonstrated previously, elimination of guanylin 
hormone expression was universal, and all TAs analyzed here exhibited complete loss of GUCA2A 
protein compared to NATs (p<0.01; Fig. 1B-D). Similarly, GUCA2A mRNA expression was reduced 
in adenomas compared to normal colonic mucosa (Fig 1E). In contrast to the hormone, the tumor 
suppressing receptor GUCY2C mRNA and protein was retained in TAs compared to normal 
mucosa (Fig. 1F-I), in alignment with previous transcriptomic and immunohistochemical analyses 
of CRCs from patients (18, 19). Again, receptor expression was universal, and TAs analyzed here 
exhibited a 25-fold increase in GUCY2C protein compared to NATs (p<0.05; Fig. 1G-I). 
3.3. SERRATED ADENOMAS 
As in TAs, hormone loss was universal and SAs exhibited reduced expression (p<0.001) of 
GUCA2A protein (Fig. 2A-C). Similarly, GUCA2A mRNA expression also was reduced in SAs 
compared to normal colonic mucosa (Fig. 2D). Unexpectedly, expression of GUCY2C mRNA and 
protein was eliminated in almost all SAs (Fig. 2E-H), in striking contrast to receptor retention 
observed in TAs (Fig. 1E-H). Again, receptor loss was universal, and all SAs exhibited reduced 
expression (p<0.001) of GUCY2C protein compared to NAT (Fig. 2G-H). Co-staining CDX2 and 
GUCY2C in human SAs confirmed loss of GUCY2C receptor with absent nuclear CDX2 staining (Fig. 
2F; Supplementary Fig. 3A-B). Indeed, retention of CDX2 expression within a crypt was associated 
with preservation of GUCY2C expression and normal morphology (arrowhead in Fig. 2F, I). 
Moreover, TCGA data revealed a direct relationship between CDX2 and GUCY2C in colonic 
adenocarcinomas (correlation coefficient: 0.74, Supplementary Fig. 4). 
Serrated tumors from mouse cecum in CDX2P-CreERT2-Cdx2FL/FL-BrafV600E mice recapitulated 
GUCA2A loss observed in human SAs (Fig. 3A). Indeed, GUCA2A protein (Fig. 3B) and mRNA (Fig. 
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3C) were reduced in serrated tumors compared to Wt controls. In contrast, GUCA2A mRNA and 
protein were preserved in tissues from Cre recombinase-negative, CDX2P-CreERT2-Cdx2FL/FL or 
mutant BrafV600E mice (Fig. 3A-C). Similarly, GUCY2C protein and mRNA were reduced in serrated 
tumors from CDX2P-CreERT2-Cdx2FL/FL-BrafV600E mice compared to Wt controls (Fig. 3D-F). 
GUCY2C protein and mRNA were unchanged in tissues from Cre recombinase-negative and 
mutant BrafV600E mice compared to Wt controls. In contrast, GUCY2C mRNA and protein were 
reduced in tissues from CDX2P-CreERT2-Cdx2FL/FL mice (Fig. 3D-F). Quantitative differences 
between changes in mRNA and protein expression reflect the mosaicism of gene loss following 
activation of Cre recombinase by tamoxifen. In that context, protein expression was analyzed in 
homogenous transformed tissues visualized by IF, compared to analyses of mRNA which 
quantifies expression in heterogeneous samples of tumor admixed with NAT. 
3.4. MSI TUMORS 
The foregoing analyses reveal differences in expression of components of the GUCA2A-GUCY2C 
axis in tumors arising from the APC-β-catenin and CDX2-Braf pathways that, in turn, have 
implications for their utility as targets for cancer prevention and therapy. These differences 
underscore the necessity of defining their expression in CRC tumors initiating through divergent 
molecular pathways. In that context, inactivation of DNA mismatch repair genes through 
hypermethylation or heritable mutations creates MSI contributing to HNPCC and Lynch 
Syndrome (8, 12, 13). As in tumors arising through the APC-β-catenin and CDX2-Braf pathways, 
GUCA2A protein and mRNA expression was lost in human MSI tumors (Fig. 4A-E). However, in 
contrast to tumors arising through the CDX2-Braf pathway, GUCY2C mRNA and protein 
expression was retained in MSI tumors (Fig. 4F-I), which was comparable to tumors arising 
through the APC-β-catenin pathway. TCGA data confirmed loss of GUCA2A, but retention of 
GUCY2C, mRNA in MSI and MSS tumors (Supplementary Figs. 1-2). 
Msh2FL/FL mice develop jejunal tumors (Fig. 5A-B) with complete loss of the DNA mismatch repair 
protein MSH2 compared to Wt controls (Fig 5C-D) (25). While GUCA2A is almost exclusively the 
GUCY2C ligand expressed in colon, GUCA2B is the primary ligand expressed in small intestine 
(14). In agreement with human MSI tumors from colon, jejunal tumors from Msh2FL/FL mice 
exhibited loss of GUCA2A (Fig. 5E-G) and GUCA2B (Fig. 5H) protein. Interestingly, the mRNA for 
these ligands was not significantly different between wild type and Msh2FL/FL tumors (Fig. 5I-J). 
Again, in agreement with human tumors, GUCY2C protein and mRNA were retained in Msh2FL/FL 
tumors (Fig. 5K-N). 
4. DISCUSSION 
CRC continues to be the fourth leading cause of cancer and the second leading cause of cancer 
mortality, underscoring the significant unmet clinical need for effective prevention and therapy 
(30). The well-established adenoma-carcinoma sequence, involving stepwise accumulation of 
genetic alterations resulting in sequential epithelial transformation over a 20-year horizon, offers 
unique opportunities to interrupt the formation of invasive and metastatic tumors by 
premalignant screening and removal, or chemoprevention (2, 3). However, surveillance has 
proven inadequate and only 63% of eligible patients in the U.S. underwent regular screening in 
2015 (31). Moreover, chemoprevention is limited to low-dose aspirin only in patients 50-59 years 
old with increased risk of cardiovascular disease and without increased risk for bleeding (32). 
Beyond prevention, >50% of patients who develop CRC die of metastatic disease (30). Identifying 
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patients who will develop metastases remains a diagnostic dilemma (20). Further, there are no 
therapeutic modalities that cure metastases. Thus, identifying and validating new targets for 
prevention and therapy remain a priority. 
While the evolution of CRC reflects a final common clinical pathway, there is recognition that 
these tumors arise through different genetic alterations. Tumors originating from the 
conventional pathway represent ~75% of sporadic CRCs and involve driver mutations in APC and 
CTNNB1 genes constitutively activating β-catenin-dependent WNT signaling (1-3). These tumors 
are characterized by CIN resulting in the development of a median of >60 mutations, including 
critical driver mutations in TP53, SMAD4 and/or KRAS contributing to invasion and metastasis (3). 
Alternatively, tumors originating from the serrated pathway represent ~20% of sporadic CRCs 
and frequently have driver mutations in MAPK pathway components, particularly BRAFV600E, that 
promote DNA hypermethylation and CIMP (4). In turn, hypermethylation silences expression of 
CDX2, producing an epithelial stem-like niche permissive for mutant BRAF to drive 
transformation (33). Finally, MSI tumors comprise ~15% of CRCs and reflect silencing of DNA 
mismatch repair genes, through mutations in inherited syndromes like HNPCC (Lynch Syndrome) 
or through hypermethylation in sporadic tumors, that leads to a hypermutable phenotype (8, 12, 
13). This diversity in CRC initiation and evolution, characterized by different genetic drivers and 
dysregulated signaling pathways, highlights the importance of defining molecular targets in 
specific tumor types to individualize clinical utility. 
The GUCY2C hormone axis has emerged as a marker and target for managing patients across the 
CRC disease continuum from prevention to metastatic therapy. GUYC2C is a tumor-suppressing 
receptor whose silencing drives transformation, including hyperproliferation, Warburg 
metabolism, genomic instability, and desmoplasia (16, 17). Further, CRC is characterized by loss 
of GUCA2A expression, which silences GUCY2C contributing to transformation (18, 19). 
Additionally, GUCY2C ligands prevent transformation induced by mutations, carcinogens, or 
inflammation in preclinical models (17, 19). These observations support a role for oral hormone 
replacement to reconstitute GUCY2C signaling as chemoprevention for CRC (34). Beyond 
prevention, tissue-selective expression on normal epithelial cells confined to intestine, but over-
expression on cancer cells, makes GUCY2C a sensitive and specific marker of occult metastatic 
tumor cells in lymph nodes and blood, that improves staging and post-operative surveillance of 
CRC patients (20). Moreover, normally GUCY2C is sequestered in apical membranes of epithelial 
cells in the luminal mucosa but represents a neoantigen in the systemic compartment in 
metastatic disease (35). This anatomical and immunological compartmentalization makes 
GUCY2C uniquely suited as a therapeutic target to eradicate established metastases with 
antibody-drug conjugates (21) and adoptive immune cell therapies (36), and to prevent the 
development of secondary metastases with vaccines, without intestinal toxicities (35). However, 
this broad applicability in CRC prevention and therapy is contingent on differential expression of 
GUYC2C signaling components in tumors arising through different canonical genetic pathways. 
Here, we defined the expression of GUCA2A and GUCY2C in tumors arising through conventional, 
serrated and MSI pathways. This study revealed the loss of GUCA2A at the earliest stages in the 
development of precancerous lesions of conventional and serrated pathways as well as in 
hereditary and sporadic MSI tumors. These observations confirm previous studies exploring the 
expression of GUCA2A in intestinal tumors arising in mice and humans (18, 19). In that regard, 
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they are consistent with the mechanistic hypothesis that paracrine hormone loss silencing the 
GUCY2C-cGMP signaling axis universally contributes to initiation and promotion of intestinal 
tumorigenesis arising through each of the canonical genetic mechanisms. Further, GUCY2C 
expression was preserved in conventional adenomas and cancers, and tumors arising through 
the MSI pathway. Surprisingly, we observed complete loss of GUCY2C in tumors arising through 
the serrated pathway. These observations validate prior studies describing the general 
association of GUCY2C expression in most, but not all, colorectal tumors (20, 37). They reinforce 
the role of silencing the GUYC2C tumor suppressor, here defined by hormone and/or receptor 
loss, as an integral component of the process of transformation generally in mice and humans. 
Moreover, they underscore the importance of exploring the expression of individual markers by 
tumors arising through discreet molecular mechanisms to define their suitability for clinical 
application. Indeed, these studies reveal that, in contrast to tumors arising through the 
conventional and MSI pathways, those arising through the serrated pathway would not be 
amenable to prevention, diagnosis or therapy targeting GUCY2C. In that context, the 
reconstitution of GUCY2C-cGMP signaling in premalignant lesions of the colorectum arising 
through the conventional and MSI pathways aimed at preventing malignant transformation 
remains an area of active investigation. Current work has direct translational relevance as the 
paradigm of GUCY2C reactivation may not be applicable to the serrated neoplasia pathway due 
to the loss of GUCY2C receptors. 
Although loss of GUCA2A is a universal feature characterizing tumorigenesis initiated through 
conventional, serrated, and MSI pathways, molecular mechanisms eliminating paracrine 
hormone expression remain incompletely defined. Indeed, regulation of GUCA2A transcription 
and translation has not been characterized previously. GUCA2A expression is suppressed in the 
colorectum by endoplasmic reticulum (ER) stress induced by consumption of excess calories in 
mice and humans (17). In part, loss of GUCA2A, associated with silencing of the GUCY2C tumor 
suppressor, by ER stress produced by excess calories is one molecular mechanism contributing 
to colorectal transformation in the context of obesity (17). However, the precise contribution of 
ER stress to the pathophysiology of cancer generally, and to different pathways driving colorectal 
cancer specifically, remains to be elucidated. Beyond ER stress, GUCA2A expression is eliminated 
as an early event in intestinal mucosa of mice heterozygous for APC mutations (18, 19). These 
observations are compatible with a model in which constitutive activation of Wnt signaling, 
through accumulation of nuclear β-catenin, regulates transcriptional programs associated with 
silencing of GUCA2A expression (15). This possibility is strengthened by the frequency of 
mutations in Wnt pathway components, resulting in constitutive activation, as part of the 
mechanism mediating transformation in serrated and MSI pathways (8, 38). In that context, we 
are exploring the role of transcriptional regulation of GUCA2A expression by constitutively 
activated Wnt signaling in tumors arising through different genomic pathways. 
While molecular processes underlying GUCA2A loss in CRC tumorigenesis remain to be defined, 
there are clear mechanistic insights into the differential loss of GUCY2C expression in tumors 
arising through the serrated, but not conventional or MSI, pathway. In that context, loss of CDX2 
expression through hypermethylation is a key step in providing the context for mutations in BRAF 
to drive tumorigenesis (9, 33). Indeed, here, CDX2 expression was eliminated in tumors arising 
through the serrated, but not the conventional or MSI, pathway. Previous studies have 
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demonstrated that intestine-specific expression of GUCY2C is driven by the canonical 
transcriptional activity of the CDX2 homeobox protein in mice and humans (39). Further, 
colorectal tumors which are deficient in CDX2 also lose GUCY2C expression (40). Additionally, 
transcriptomic analyses revealed a direct relationship between CDX2 and GUCY2C expression 
(see Supplementary Fig. 4). Finally, while isolated mutations in Braf had no effect, elimination of 
CDX2 expression alone reduced expression of GUCY2C in mouse colonic mucosa (see Fig. 3). 
Taken together, these observations support the role of CDX2 in driving intestine-specific 
expression of GUCY2C and its loss in tumors arising through the serrated, but not conventional 
or MSI, pathway. 
These studies establish loss of GUCA2A and silencing of GUCY2C as universal features of intestinal 
tumorigenesis produced by conventional, serrated and MSI pathways (17-19). They re-enforce 
the utility of hormone loss as an actionable mechanism to develop strategies using oral GUCY2C 
ligand replacement to prevent the development of tumors arising through the conventional 
pathway (17, 19). In the context of the preservation of GUCY2C expression, these observations 
also suggest that oral hormone replacement might be a useful strategy to prevent tumors arising 
through the MSI pathway. This possibility is underscored by the role of the GUCY2C-cGMP 
signaling axis in amplifying DNA repair mechanisms and preventing injury and transformation by 
DNA damaging agents (16, 17, 28, 41). The immediate translational application of these 
observations can be appreciated by considering that the oral GUCY2C ligands linaclotide 
(Linzess™) and plecanatide (Trulance™) are approved to treat chronic constipation syndromes. 
Importantly, these studies reveal that GUCY2C expression is preserved in tumors arising through 
conventional and MSI, but not serrated, pathways. In turn, they suggest the utility of GUCY2C-
tageted therapies, including antibody-drug conjugates, adoptive cell therapies and cancer 
vaccines, to prevent or treat metastatic disease originating from tumors arising through 




S.A.W. is the Samuel MV Hamilton Professor of Medicine of Thomas Jefferson University. The 
authors would like to thank Dr. Winfried Edelmann for providing Msh2FL/FL mice. Also, we would 
like to thank Dr. Melanie Kucherlapati for providing mouse tumors from MSH2 knockout mice. 
We are grateful to Ms. Elinor Leong for technical assistance with RNA isolation and qRT-PCR 





1. Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi M-C, 
Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou J-F, Benchimol D, Berger A, Lagarde A, 
Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V. Gene 
expression classification of colon cancer into molecular subtypes: characterization, validation, 
and prognostic value. PLOS Medicine 2013; 10, e1001453. 
2. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation 
of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997; 275, 
1787-1790. 
3. Strum WB. Colorectal adenomas. New England Journal of Medicine 2016; 374, 1065-
1075. 
4. Langner C. Serrated and non-serrated precursor lesions of colorectal cancer. Digestive 
Diseases 2015; 33, 28-37. 
5. Wynter CVA, Walsh MD, Higuchi T, Leggett BA, Young J, Jass JR. Methylation patterns 
define two types of hyperplastic polyp associated with colorectal cancer. Gut 2004; 53, 573-
580. 
6. Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal 
cancer: clinical characteristics, clinical behavior, and response to targeted therapies. Journal of 
Gastrointestinal Oncology 2015; 6, 660-667. 
7. Yang S, Farraye FA, Mack C, Posnik O, O'Brien MJ. BRAF and KRAS Mutations in 
hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and 
CpG island methylation status. The American journal of surgical pathology 2004; 28, 1452-1459. 
8. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 
138, 2073-2087.e2073. 
9. Balbinot C, Armant O, Elarouci N, Marisa L, Martin E, De Clara E, Onea A, Deschamps J, 
Beck F, Freund J-N, Duluc I. The Cdx2 homeobox gene suppresses intestinal tumorigenesis 
through non–cell-autonomous mechanisms. The Journal of Experimental Medicine 2018; 215, 
911-926. 
10. Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgó E, 
Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van 
de Rijn M, Clarke MF. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. 
New England Journal of Medicine 2016; 374, 211-222. 
11. Landau MS, Kuan S-F, Chiosea S, Pai RK. BRAF-mutated microsatellite stable colorectal 
carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 
immunohistochemical expression. Human Pathology; 45, 1704-1712. 
12. Sinicrope FA. Lynch syndrome-associated colorectal cancer. The New England journal of 
medicine 2018; 379, 764-773. 
13. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs 
CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical 
outcome in colon cancer. Gut 2009; 58, 90-96. 
14. Kuhn M. Molecular physiology of membrane guanylyl cyclase receptors. Physiol Rev 
2016; 96, 751-804. 
15. Pattison AM, Merlino DJ, Blomain ES, Waldman SA. Guanylyl cyclase C signaling axis and 
colon cancer prevention. World journal of gastroenterology 2016; 22, 8070-8077. 
 15 
16. Li P, Schulz S, Bombonati A, Palazzo JP, Hyslop TM, Xu Y, Baran AA, Siracusa LD, Pitari 
GM, Waldman SA. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting 
proliferation and maintaining genomic integrity. Gastroenterology 2007; 133, 599-607. 
17. Lin JE, Colon-Gonzalez F, Blomain E, Kim GW, Aing A, Stoecker B, Rock J, Snook AE, Zhan 
T, Hyslop TM, Tomczak M, Blumberg RS, Waldman SA. Obesity-Induced Colorectal Cancer Is 
Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis. Cancer research 
2016; 76, 339-346. 
18. Cohen MB, Hawkins JA, Witte DP. Guanylin mRNA expression in human intestine and 
colorectal adenocarcinoma. Laboratory investigation; a journal of technical methods and 
pathology 1998; 78, 101-108. 
19. Shailubhai K, Yu HH, Karunanandaa K, Wang JY, Eber SL, Wang Y, Joo NS, Kim HD, 
Miedema BW, Abbas SZ, Boddupalli SS, Currie MG, Forte LR. Uroguanylin treatment suppresses 
polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon 
adenocarcinoma cells via cyclic GMP. Cancer Res 2000; 60, 5151-5157. 
20. Waldman SA, Hyslop T, Schulz S, Barkun A, Nielsen K, Haaf J, Bonaccorso C, Li Y, 
Weinberg DS. Association of GUCY2C expression in lymph nodes with time to recurrence and 
disease-free survival in pN0 colorectal cancer. JAMA 2009; 301, 745-752. 
21. Marszalowicz GP, Snook AE, Magee MS, Merlino D, Berman-Booty LD, Waldman SA. 
GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal 
cancer. Oncotarget 2014; 5, 9460-9471. 
22. Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, 
Eisenlohr LC, Waldman SA. Lineage-specific T-cell responses to cancer mucosa antigen oppose 
systemic metastases without mucosal inflammatory disease. Cancer Res 2009; 69, 3537-3544. 
23. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse 
model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. 
Genes Dev 2007; 21, 379-384. 
24. Sakamoto N, Feng Y, Stolfi C, Kurosu Y, Green M, Lin J, Green ME, Sentani K, Yasui W, 
McMahon M, Hardiman KM, Spence JR, Horita N, Greenson JK, Kuick R, Cho KR, Fearon ER. 
BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis. 
eLife 2017; 6, e20331. 
25. Kucherlapati MH, Lee K, Nguyen AA, Clark AB, Hou H, Jr., Rosulek A, Li H, Yang K, Fan K, 
Lipkin M, Bronson RT, Jelicks L, Kunkel TA, Kucherlapati R, Edelmann W. An Msh2 conditional 
knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology 
2010; 138, 993-1002.e1001. 
26. Valentino MA, Lin JE, Snook AE, Li P, Kim GW, Marszalowicz G, Magee MS, Hyslop T, 
Schulz S, Waldman SA. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. The 
Journal of Clinical Investigation; 121, 3578-3588. 
27. Moss NG, Fellner RC, Qian X, Yu SJ, Li Z, Nakazato M, Goy MF. Uroguanylin, an Intestinal 
Natriuretic Peptide, Is Delivered to the Kidney as an Unprocessed Propeptide. Endocrinology 
2008; 149, 4486-4498. 
28. Li P, Wuthrick E, Rappaport JA, Kraft C, Lin JE, Marszalowicz G, Snook AE, Zhan T, Hyslop 
TM, Waldman SA. GUCY2C signaling opposes the acute radiation-induced GI syndrome. Cancer 
Res 2017; 77, 5095-5106. 
 16 
29. The Cancer Genome Atlas N. Comprehensive molecular characterization of human colon 
and rectal cancer. Nature 2012; 487, 330. 
30. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians 
2018; 68, 7-30. 
31. Health, United States, 2015: With Special Feature on Racial and Ethnic Health 
Disparities. Hyattsville (MD): National Center for Health Statistics, 2016. 
32. Bibbins-Domingo K, on behalf of the USPSTF. Aspirin use for the primary prevention of 
cardiovascular disease and colorectal cancer: U.s. preventive services task force 
recommendation statement. Annals of Internal Medicine 2016; 164, 836-845. 
33. Tong K, Pellón-Cárdenas O, Sirihorachai VR, Warder BN, Kothari OA, Perekatt AO, Fokas 
EE, Fullem RL, Zhou A, Thackray JK, Tran H, Zhang L, Xing J, Verzi MP. Degree of Tissue 
Differentiation Dictates Susceptibility to BRAF-Driven Colorectal Cancer. Cell Reports 2017; 21, 
3833-3845. 
34. Weinberg DS, Lin JE, Foster NR, Della'Zanna G, Umar A, Seisler D, Kraft WK, Kastenberg 
DM, Katz LC, Limburg PJ, Waldman SA. Bioactivity of Oral Linaclotide in Human Colorectum for 
Cancer Chemoprevention. Cancer Prev Res (Phila) 2017; 10, 345-354. 
35. Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, 
Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic 
responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst 2008; 100, 
950-961. 
36. Magee MS, Abraham TS, Baybutt TR, Flickinger JC, Jr., Ridge NA, Marszalowicz GP, 
Prajapati P, Hersperger AR, Waldman SA, Snook AE. Human GUCY2C-targeted chimeric antigen 
receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Res 
2018; 6, 509-516. 
37. Winn B, Tavares R, Matoso A, Noble L, Fanion J, Waldman SA, Resnick MB. Expression of 
the intestinal biomarkers guanylyl cyclase C and CDX2 in poorly differentiated colorectal 
carcinomas. Human pathology 2010; 41, 123-128. 
38. Borowsky J, Dumenil T, Bettington M, Pearson SA, Bond C, Fennell L, Liu C, McKeone D, 
Rosty C, Brown I, Walker N, Leggett B, Whitehall V. The role of APC in WNT pathway activation 
in serrated neoplasia. Mod Pathol 2018; 31, 495-504. 
39. Park J, Schulz S, Waldman SA. Intestine-specific activity of the human guanylyl cyclase C 
promoter is regulated by Cdx2. Gastroenterology 2000; 119, 89-96. 
40. Winn B, Tavares R, Matoso A, Noble L, Fanion J, Waldman SA, Resnick MB. Expression of 
the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal 
carcinomas. Human pathology 2010; 41, 123-128. 
41. Lin JE, Li P, Snook AE, Schulz S, Dasgupta A, Hyslop TM, Gibbons AV, Marszlowicz G, 
Pitari GM, Waldman SA. The hormone receptor GUCY2C suppresses intestinal tumor formation 
by inhibiting AKT signaling. Gastroenterology 2009; 138, 241-254. 
  
 17 
Table 1. Patient characteristics 










7:11 5:10 3:4 3:4 
Median age in 
years (IQR) 
54 (47-70) 65 (55-69) 50 (44-77) 60 (41-61) 
Proximal:distal 
colona 
8:10 10:5 2:5 6:1 
NAT present 55% 80% - 86% 
Subtype Tubular                7 
Tubulovillous      8 
Villous                  1 
FAP                       2 
SSA                    13  
TSA                    2    
- Sporadic         3 
Hereditary     4 
Abbreviations: FAP=familial adenomatous polyposis; IQR=interquartile range; 
MSI=microsatellite instability; NAT=normal adjacent tissue; SSA=sessile serrated adenoma; 
TSA=traditional serrated adenoma. 





Figure 1. GUCA2A, but not GUCY2C, is lost in tubular adenomas. (A) Representative H&E image 
of normal colon and tubular adenoma. (B) Representative immunofluorescence (IF) image of 
human tubular adenomas and normal colonic mucosa with GUCA2A immunostain. (C-D) GUCA2A 
(green) quantified by IF (B) in tubular adenomas and normal adjacent mucosa (NAT) in matched 
(n=9; C) and unmatched (n=18; D) specimens. (E) GUCA2A mRNA quantified by RT-PCR in tubular 
adenomas (n=9) compared to normal colonic mucosa (n=8). (F) GUCY2C mRNA quantified by RT-
PCR in tubular adenomas (n=9) compared to normal colonic mucosa (n=8). (G-I) GUCY2C (green; 
F) quantified by IF in tubular adenomas and NATs in matched (n=9; G) and in unmatched (n=18; 
H) specimens. (Purple, CDX2; blue, DAPI). *, p<0.05; **, p<0.01, ****, p<0.0001. Scale bar=100 
µm. 
Figure 2. GUCY2C and GUCA2A are lost in serrated adenomas. (A) Representative 
immunofluorescence (IF) image of human serrated adenomas and normal colonic mucosa. (A-C) 
GUCA2A (green) quantified by IF (A) in serrated adenomas compared to NAT in matched (n=12; 
B) and unmatched (n=15; C) specimens. (D) GUCA2A and (E) GUCY2C mRNA quantified by RT-PCR 
in serrated adenomas (n=6) compared to normal colonic mucosa (n=6). (F-H) GUCY2C (green) 
quantified by IF (F) in serrated adenomas and NATs in matched (n=9; G) and unmatched (n=18; 
H) specimens. (I) Representative H&E image of normal colon and serrated adenoma. Arrowhead 
on F and I corresponds to a normal appearing crypt (I) with preservation of CDX2 and GUCY2C 
staining (F). (Purple, CDX2; blue, DAPI). *, p<0.05; ***, p<0.001, ****, p<0.0001. Scale bar=100 
µm. 
Figure 3. GUCA2A and GUCY2C expression following Cdx2 inactivation and/or BrafV600E 
mutation in mice. (A) Representative IF images of expression of GUCA2A (green) from CDX2P-
CreERT2-Cdx2fl/fl (Cdx2fl/fl), CDX2P-CreERT2-BrafCA (BrafV600E), CDX2P-CreERT2-Cdx2fl/fl-BrafCA 
(Cdx2fl/fl-BrafV600E), CreERT2 negative control (Cre-) and wild type control mice. (B) IF quantification 
revealed decreased GUCA2A expression in serrated tumors (n=8) from compound Cdx2fl/fl-
BrafV600E mice, but not Cre- control (n=6), Cdx2fl/fl (n=3) or BrafV600E (n=3) mice, compared to wild 
type controls (n=6). (C) GUCA2A mRNA was reduced in serrated tumors from compound Cdx2fl/fl 
BrafV600E mice, but not in Cdx2fl/fl or BrafV600E mice, compared to wild type controls (n=3). (D) 
Representative IF images of expression of GUCY2C (green) and CDX2 (purple) from CDX2P-
CreERT2-Cdx2fl/fl (Cdx2fl/fl), CDX2P-CreERT2-BrafCA (BrafV600E), CDX2P-CreERT2-Cdx2fl/fl-BrafCA 
(Cdx2fl/fl-BrafV600E), CreERT2 negative control (Cre-) and wild type control mice. (E) IF quantification 
revealed decreased GUCY2C expression in serrated tumors (n=8) from compound Cdx2fl/fl 
BrafV600E mice compared to wild type controls (n=6). GUCY2C expression was also reduced in 
Cdx2fl/fl (n=3) mice compared to wild type controls, but not in Cre- control (n=6), or BrafV600E (n=3) 
mice. (F) GUCY2C mRNA was reduced in both Cdx2fl/fl and serrated tumors in compound Cdx2fl/fl 
BrafV600E mice but not in BrafV600E mice, compared to wild type controls (n=3). Blue, DAPI. **, 
p<0.01, ****, p<0.0001. Scale bar=100 µm. 
Figure 4. GUCA2A, but not GUCY2C, is lost in microsatellite unstable (MSI) tumors. (A) 
Representative H&E image of normal colon and MSI tumor. (B) Representative 
immunofluorescent (IF) images of MSI tumors and normal colonic mucosa. (C-D) GUCA2A (green) 
quantified by IF (B) in MSI tumors and NATs in matched (n=5; C) and unmatched (n=7; D) 
specimens. (E) GUCA2A mRNA quantified by RT-PCR in MSI tumors (n=6) compared to normal 
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colonic mucosa (n=7). (F) GUCY2C mRNA quantified by RT-PCR in MSI tumors (n=6) compared to 
normal colonic mucosa (n=7). (G-I) GUCY2C (green) quantified by IF (G) in MSI tumors and NATs 
in matched (n=5; H) and unmatched (n=7; I) specimens. (Purple, CDX2; blue, DAPI). *, p<0.05; **, 
p<0.01. Scale bar=100 µm. 
Figure 5. GUCA2A and GUCY2C in enterocytes following biallelic Msh2 inactivation in mice. 
Constitutively active vil-Cre-Msh2fl/fl (Msh2-/-) mice developed jejunal tumors (A, gross 
appearance; B, microscopic appearance). (C-D) Representative immunofluorescent (IF) image 
and quantification of MSH2 protein expression (purple) in Msh2-/- tumors (n=3) compared to age-
matched wild type controls (n=3). (E-F) (GUCA2A, green; β-catenin, red) from Msh2-/- tumors 
(n=5) compared to age-matched wild type controls (n=5) reveals loss of GUCA2A expression. (G) 
GUCA2A protein expression was reduced by immunoblot analysis (n=5). (H) GUCA2B protein 
expression was reduced by immunoblot analysis (n=5). GUCA2A (I) and GUCY2B (J) mRNA 
quantified by RT-PCR in Msh2-/- tumors (n=5) were not reduced compared to age-matched wild 
type controls (n=6). (K-L) Representative IF images (GUCY2C, green; CDX2, purple) from Msh2-/- 
tumors (n=10) compared to age-matched wild type controls (n=6) reveal no change in GUCY2C 
protein expression. (M-N) GUCY2C protein by immunoblot analysis (n=5) and mRNA (n=5) was 
unchanged in Msh2-/- tumors compared to Wt controls (n=6). Blue, DAPI. *, p<0.05; **, p<0.01. 
****, p<0.0001. Scale bar=100 µm. 
